MAGE-A4ᶜ¹⁰³²T for Multi-Tumor
Trial ID: NCT03132922
Phase: Phase 1
Status: Active but not recruiting
Last Update Posted: June 2026
Please Note: This trial is no longer enrolling new patients but remains active for long-term follow-up of enrolled participants.
Eligibility: Adults aged 18 to 75 with advanced synovial sarcoma expressing the MAGE-A4 antigen who are HLA-A*02 positive, have measurable disease, and have progressed after prior standard therapies.
Overview: This Phase 1 trial evaluates MAGE-A4ᶜ¹⁰³²T, a TCR-engineered T-cell therapy in which a patient’s own T-cells are modified to recognize and attack tumor cells expressing MAGE-A4. The trial also includes a radiation sub-study evaluating the combination of MAGE-A4ᶜ¹⁰³²T with low-dose radiation in up to 10 patients who have at least one tumor lesion amenable to radiation.
Preliminary Effectiveness: Results published in Nature Medicine (January 2023) demonstrated an overall response rate of approximately 39% across evaluable patients, with some experiencing significant tumor shrinkage and disease stabilization lasting a median of approximately 12 months, indicating potential durable benefit in this patient population.
Treatment Centers: USA, Canada